vininews.com
vininews.com Veritas, Inquiry, News & Intelligence

Verified source report

STAT+: Capricor Therapeutics accuses Nippon Shinyaku of slow-walking plans on Duchenne drug

Capricor Therapeutics has accused Nippon Shinyaku and its U.S. subsidiary of botching the rollout of a Duchenne muscular dystrophy treatment.

Image for STAT+: Capricor Therapeutics accuses Nippon Shinyaku of slow-walking plans on Duchenne drug
Source image associated with the linked report from STAT.Credit: Image via STAT Source-hosted image; rights remain with the publisher or credited rights holder. Image source Image selected from source-page metadata and displayed with attribution and link back; VINI does not copy the image into local storage unless rights are cleared.
Vinita Duniphin Briefs Source report

What happened

According to STAT’s source item, STAT+: Capricor Therapeutics accuses Nippon Shinyaku of slow-walking plans on Duchenne drug, Capricor Therapeutics has accused Nippon Shinyaku and its U.S. subsidiary of botching the rollout of a Duchenne muscular dystrophy treatment.

Context

The development sits in VINI’s Science file for readers following research, health, climate, space, medicine, and scientific institutions. The original report is linked so readers can check the source account, follow later updates, and compare new coverage against the first published record. The source item is dated 2026-05-08T18:32:59+00:00.

What to watch

Open questions include whether primary sources issue follow-up statements, whether local or market impacts become clearer, and whether additional reporting changes the timeline or adds material context.

Source

Primary source: STAT+: Capricor Therapeutics accuses Nippon Shinyaku of slow-walking plans on Duchenne drug via STAT. VINI cites and links the source; it does not reproduce the publisher’s full article text without rights clearance.

This source-cited VINI report links to the original publisher record. VINI does not republish third-party article bodies without rights clearance. 1 source listed.

Source links

Reader comments

Moderated discussion

Account access

Comments are open to authenticated approved accounts, screened for spam and abuse, and published only after newsroom moderation unless editors change the story control.

Loading comments.